Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2971570 | 0.88 | NOTUM (0.53) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL2978942 | 0.87 | KDM1A (0.51) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL8225943 | 0.87 | HDAC1 (0.52) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL12316020 | 0.85 | KDM1A (0.50) | HDAC1HDAC8HDAC6KDM1AUSP30 | |
| SCHEMBL18193871 | 0.82 | KDM1A (0.55) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL13989330 | 0.79 | NOTUM (0.65) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL13203987 | 0.79 | NOTUM (0.42) | HDAC1HDAC8HDAC6NOTUMTSHR | |
| SCHEMBL2984971 | 0.78 | NOTUM (0.48) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL4525832 | 0.78 | KDM1A (0.49) | HDAC1HDAC8HDAC6KDM1ANOTUM | |
| SCHEMBL18133613 | 0.78 | HDAC1 (0.59) | HDAC1HDAC8HDAC6KDM1ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| WO-2008021545-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063021-A9 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HDAC1 1652/4885HDAC8 1819/4885HDAC6 1262/4885 |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | HRH2, ACHE, CHRM2 | HDAC1 1551/4885HDAC8 3164/4885HDAC6 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.